Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunit... Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunity. Its portfolio features key products such as JAKAFI (ruxolitinib), approved for intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; OPZELURA, addressing atopic dermatitis and vitiligo in the dermatology segment; and MONJUVI/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma. Additional offerings include PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor, alongside NIKTIMVO, ZYNYZ, and ICLUSIG, contributing to its expanding hematology and oncology segments. Incyte Corporation also generates royalty revenues from partnered products like Jakavi and Olumiant. The company operates across the United States, Europe, Canada, and Japan, advancing a pipeline of candidates in oncology and immunology to address unmet medical needs. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte Corporation plays a significant role in delivering targeted therapies for complex diseases.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Incyte is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Incyte is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Incyte's data?

Start your 30-day free trial to request a data review for Incyte.

Start Free Trial

Legal Center Contact Us